“Today’s FDA approval of VANFLYTA is an important milestone, as patients with the FLT3-ITD subtype of AML can now be treated with the first ever …
FDA Clears Daiichi Sankyo’s Newly Diagnosed Acute Myeloid Leukemia Drug
Share This Story, Choose Your Platform!
About the Author:
